Management of recurrent endometrioid endometrial carcinoma: An overview

International Journal of Gynecological Cancer

Volumn 19, Issue 3, 2009, Pages 314-320

  Van Wijk, F H ^a   Van Der Burg, M E L ^a   Burger, Curt W ^b   Vergote, Ignace ^a   Van Doorn, Helena C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b University Hospitals Leuven   (Netherlands)

Author keywords

Endometrial cancer; Management; Recurrent

Indexed keywords

ANASTROZOLE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GESTAGEN; GOSERELIN; HORMONE; HYDROXYPROGESTERONE CAPROATE; LETROZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PACLITAXEL; PROGESTERONE; TAMOXIFEN;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FUNCTIONAL STATUS; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TUMOR LOCALIZATION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL;

EID: 68149169043     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a7f71e     Document Type: Review

References (90)

1. Fung-Kee-Fung M., Dodge J., Elit L., et al. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol. 2006;101:520-529.
2. Lin LL, Grigsby PW, Powell MA, et al. Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer. Int J Radiat Oncol Biol Phys. 2005;63:500-504.
3. Tewari K., Cappuccini F., Brewster WR, et al. Interstitial brachytherapy for vaginal recurrences of endometrial carcinoma. Gynecol Oncol. 1999;74:416-422.
4. Markman M. Hormonal therapy of endometrial cancer. Eur J Cancer. 2005;41:673-675.
5. Neijt JP. Systemic treatment in disseminated endometrial cancer. Eur J Cancer. 1993;29A:628-632.
6. Moore TD, Phillips PH, Nerenstone SR, et al. Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J Clin Oncol. 1991;9:1071-1088.
7. Elit L., Hirte H. Novel strategies for systemic treatment of endometrial cancer. Expert Opin Investig Drugs. 2000;9:2831-2853.
8. Bridges J., Oram D. Management of advanced gynaecological malignancies. Br J Hosp Med. 1993;49:191-199.
9. Deppe G. Chemotherapeutic treatment of endometrial carcinoma. Clin Obstet Gynecol. 1982;25:93-99.
10. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17:1736-1744.
11. Quinn MA, Cauchi M., Fortune D. Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate. Gynecol Oncol. 1985;21:314-319.
12. Podratz KC, O'Brien PC, Malkasian GD Jr, et al. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol. 1985;66:106-110.
13. Piver MS, Barlow JJ, Lurain JR, et al. Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer. 1980;45: 268-272.
14. Lentz SS, Brady MF, Major FJ, et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1996;14:357-361.
15. Pandya KJ, Yeap BY, Weiner LM, et al. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol. 2001;24:43-46.
16. Emons G., Heyl W. Hormonal treatment of endometrial cancer. J Cancer Res Clin Oncol. 2000;126:619-623.
17. Bonte J., Ide P., Billiet G., et al. Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma. Gynecol Oncol. 1981;11:140-161.
18. Swenerton KD, White GW, Boyes DA. Treatment of advanced endometrial carcinoma with tamoxifen. N Engl J Med. 1979;301:105.
19. Edmonson JH, Krook JE, Hilton JF, et al. Ineffectiveness of tamoxifen in advanced endometrial carcinoma after failure of progestin treatment. Cancer Treat Rep. 1986;70:1019-1020.
20. Slavik M., Petty WM, Blessing JA, et al. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep. 1984;68:809-811.
21. Thigpen T., Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001;19:364-367.
22. Fiorica JV, Brunetto VL, Hanjani P., et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:10-14.
23. Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:4-9.
24. Gallagher CJ, Oliver RT, Oram DH, et al. A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue. Br J Obstet Gynaecol. 1991;98:1037-1041.
25. Jeyarajah AR, Gallagher CJ, Blake PR, et al. Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer. Gynecol Oncol. 1996;63:47-52.
26. Lhomme C., Vennin P., Callet N., et al. A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study. Gynecol Oncol. 1999;75:187-193.
27. Asbury RF, Brunetto VL, Lee RB, et al. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol. 2002;25:557-560.
28. Covens A., Thomas G., Shaw P., et al. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol. 1997;64: 126-129.
29. Rose PG, Brunetto VL, VanLe L., et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2000;78:212-216.
30. Ma BB, Oza A., Eisenhauer E., et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers-a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer. 2004;14:650-658.
31. Ball HG, Blessing JA, Lentz SS, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;62: 278-281.
32. Lissoni A., Zanetta G., Losa G., et al. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol. 1996;7: 861-863.
33. Ramondetta L., Burke TW, Levenback C., et al. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol. 2001;82:156-161.
34. Fleming GF, Brunetto VL, Cella D., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:2159-2166.
35. Dimopoulos MA, Papadimitriou CA, Georgoulias V., et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol. 2000;78:52-57.
36. Lissoni A., Gabriele A., Gorga G., et al. Cisplatin-, epirubicin - and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol. 1997;8:969-972.
37. Price FV, Edwards RP, Kelley JL, et al. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report. Semin Oncol. 1997;24: S15-78-S15-82.
38. Nakamura T., Onishi Y., Yamamoto F., et al. Evaluation of paclitaxel and carboplatin in patients with endometrial cancer [in Japanese]. Gan To Kagaku Ryoho. 2000;27:257-262.
39. Scudder SA, Liu PY, Wilczynski SP, et al. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecol Oncol. 2005;96:610-615.
40. Seski JC, Edwards CL, Herson J., et al. Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol. 1982;59:225-228.
41. Edmonson JH, Krook JE, Hilton JF, et al. Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma. Gynecol Oncol. 1987;28:20-24.
42. Thigpen JT, Blessing JA, Homesley H., et al. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989;33:68-70.
43. Thigpen JT, Blessing JA, Lagasse LD, et al. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol. 1984;7:253-256.
44. Horton J., Begg CB, Arseneault J., et al. Comparison of Adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep. 1978;62:159-161.
45. Horton J., Elson P., Gordon P., et al. Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens. Cancer. 1982;49:2441-2445.
46. Long HJ, Pfeifle DM, Wieand HS, et al. Phase II evaluation of carboplatin in advanced endometrial carcinoma. J Natl Cancer Inst. 1988;80:276-278.
47. Van Wijk FH, Lhomme C., Bolis G., et al. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. Eur J Cancer. 2003;39:78-85.
48. Curran WJ Jr, Whittington R., Peters AJ, et al. Vaginal recurrences of endometrial carcinoma: the prognostic value of staging by a primary vaginal carcinoma system. Int J Radiat Oncol Biol Phys. 1988;15: 803-808.
49. Burke TW, Heller PB, Woodward JE, et al. Treatment failure in endometrial carcinoma. Obstet Gynecol. 1990;75:96-101.
50. Creutzberg CL, van Putten WL, Koper PC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003;89:201-209.
51. Bristow RE, Santillan A., Zahurak ML, et al. Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecol Oncol. 2006;103:281-287.
52. Barakat RR, Goldman NA, Patel DA, et al. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol. 1999;75:99-102.
53. Fleisch MC, Pantke P., Beckmann MW, et al. Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. J Surg Oncol. 2007;95:476-484.
54. Hockel M., Dornhofer N. Pelvic exenteration for gynaecological tumours: achievements and unanswered questions. Lancet Oncol. 2006;7:837-847.
55. Morley GW, Hopkins MP, Lindenauer SM, et al. Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol. 1989;74:934-943.
56. Numa F., Ogata H., Suminami Y., et al. Pelvic exenteration for the treatment of gynecological malignancies. Arch Gynecol Obstet. 1997;259:133-138.
57. Berek JS, Howe C., Lagasse LD, et al. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol. 2005;99: 153-159.
58. Shepherd JH, Ngan HY, Neven P., et al. Multivariate analysis of factors affecting survival in pelvic exenteration. Int J Gynecol Cancer. 1994;4:361-370.
59. Jakowatz JG, Porudominsky D., Riihimaki DU, et al. Complications of pelvic exenteration. Arch Surg. 1985;120:1261-1265.
60. Lopez MJ, Standiford SB, Skibba JL. Total pelvic exenteration. A 50-year experience at the Ellis Fischel Cancer Center. Arch Surg. 1994;129: 390-395; discussion 5-6.
61. Gemignani ML, Alektiar KM, Leitao M., et al. Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers. Int J Radiat Oncol Biol Phys. 2001;50:687-694.
62. Huh WK, Straughn JM Jr, Mariani A., et al. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer. 2007;17: 886-889.
63. Jhingran A., Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys. 2003;56:1366-1372.
64. Nag S., Yacoub S., Copeland LJ, et al. Interstitial brachytherapy for salvage treatment of vaginal recurrences in previously unirradiated endometrial cancer patients. Int J Radiat Oncol Biol Phys. 2002;54:1153-1159.
65. Mandell LR, Nori D., Hilaris B. Recurrent stage I endometrial carcinoma: results of treatment and prognostic factors. Int J Radiat Oncol Biol Phys. 1985;11:1103-1109.
66. Kalogiannidis I., Lambrechts S., Amant F., et al. Role of lymphadenectomy and pelvic radiotherapy in patients with clinical FIGO stage I endometrial adenocarcinoma: an analysis of 208 patients. Int J Gynecol Cancer. 2006;16:1885-1893.
67. Poulsen MG, Roberts SJ. The salvage of recurrent endometrial carcinoma in the vagina and pelvis. Int J Radiat Oncol Biol Phys. 1988;15:809-813.
68. Wylie J., Irwin C., Pintilie M., et al. Results of radical radiotherapy for recurrent endometrial cancer. Gynecol Oncol. 2000;77:66-72.
69. Hoekstra CJ, Koper PC, van Putten WL. Recurrent endometrial adenocarcinoma after surgery alone: prognostic factors and treatment. Radiother Oncol. 1993;27:164-166.
70. Kuten A., Grigsby PW, Perez CA, et al. Results of radiotherapy in recurrent endometrial carcinoma: a retrospective analysis of 51 patients. Int J Radiat Oncol Biol Phys. 1989;17:29-34.
71. Monk BJ, Tewari KS, Puthawala AA, et al. Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation. Int J Radiat Oncol Biol Phys. 2002;52:806-815.
72. Campagnutta E., Giorda G., De Piero G., et al. Surgical treatment of recurrent endometrial carcinoma. Cancer. 2004;100:89-96.
73. Awtrey CS, Cadungog MG, Leitao MM, et al. Surgical resection of recurrent endometrial carcinoma. Gynecol Oncol. 2006;102: 480-488.
74. Scarabelli C., Campagnutta E., Giorda G., et al. Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma. Gynecol Oncol. 1998;70:90-93.
75. Hockel M. Ultra-radical compartmentalized surgery in gynaecological oncology. Eur J Surg Oncol. 2006;32:859-865.
76. Hockel M., Sclenger K., Hamm H., et al. Five-year experience with combined operative and radiotherapeutic treatment of recurrent gynecologic tumors infiltrating the pelvic wall. Cancer. 1996;77:1918-1933.
77. Dowdy SC, Mariani A., Cliby WA, et al. Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes. Gynecol Oncol. 2006; 101:280-286.
78. Helm CW, Toler CR, Martin RS 3rd, et al. Cytoreduction and intraperitoneal heated chemotherapy for the treatment of endometrial carcinoma recurrent within the peritoneal cavity. Int J Gynecol Cancer. 2007;17:204-209.
79. Aalders JG, Abeler V., Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol. 1984;17:85-103.
80. Crespo C., Gonzalez-Martin A., Lastra E., et al. Metastatic endometrial cancer in lung and liver: complete and prolonged response to hormonal therapy with progestins. Gynecol Oncol. 1999;72:250-255.
81. Dowdy SC, Mariani A., Bakkum JN, et al. Treatment of pulmonary recurrences in patients with endometrial cancer. Gynecol Oncol. 2007;107:242-247.
82. Hamy A., Letessier E., Guillard Y., et al. Splenectomy for isolated splenic metastasis from endometrial carcinoma. Acta Obstet Gynecol Scand. 1995;74:745-746.
83. Temkin SM, Hellman M., Lee YC, et al. Surgical resection of vulvar metastases of endometrial cancer: a presentation of two cases. J Low Genit Tract Dis. 2007;11:118-121.
84. Bindal RK, Sawaya R., Leavens ME, et al. Surgical treatment of multiple brain metastases. J Neurosurg. 1993;79:210-216.
85. Tangjitgamol S., Levenback CF, Beller U., et al. Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review. Int J Gynecol Cancer. 2004;14:399-422.
86. Southcott BM. Carcinoma of the endometrium. Drugs. 2001;61: 1395-1405.
87. Mutic S., Malyapa RS, Grigsby PW, et al. PET-guided IMRT for cervical carcinoma with positive para-aortic lymph nodes-a dose-escalation treatment planning study. Int J Radiat Oncol Biol Phys. 2003;55:28-35.
88. Esthappan J., Mutic S., Malyapa RS, et al. Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes. Int J Radiat Oncol Biol Phys. 2004;58:1289-1297.
89. Sneed PK, Lamborn KR, Forstner JM, et al. Radiosurgery for brain metastases: is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys. 1999;43:549-558.
90. Shiohara S., Ohara M., Itoh K., et al. Successful treatment with stereotactic radiosurgery for brain metastases of endometrial carcinoma: a case report and reviewof the literature. Int J Gynecol Cancer. 2003;13:71-76.